Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
48
FSNUY Quote, Financials, Valuation and Earnings
Last price:
$12.57
Seasonality move
:
9.89%
Day range:
$12.45 - $12.66
52-week range:
$9.78 - $33.93
Dividend yield:
2.28%
P/E ratio:
19.47x
P/S ratio:
1.08x
P/B ratio:
1.25x
Volume:
328.2K
Avg. volume:
95.5K
1-year change:
16.83%
Market cap:
$28B
Revenue:
$25.8B
EPS (TTM):
$0.64
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FSNUY
Fresenius SE & Co. KGaA
|
-- | -- | -- | -- | -- |
|
BNTX
BioNTech SE
|
$201.5M | -$1.97 | -7.26% | -35.17% | $130.51 |
|
FMS
Fresenius Medical Care AG
|
$5.6B | $0.60 | 6.34% | 113.98% | $27.17 |
|
IFRX
InflaRx NV
|
$6.4K | -$0.14 | -74.55% | -23.33% | $8.84 |
|
IMTX
Immatics NV
|
$11.7M | -$0.46 | -40.34% | -26.23% | $18.75 |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FSNUY
Fresenius SE & Co. KGaA
|
$12.57 | -- | $28B | 19.47x | $0.28 | 2.28% | 1.08x |
|
BNTX
BioNTech SE
|
$91.18 | $130.51 | $23.4B | 191.55x | $0.00 | 0% | 6.64x |
|
FMS
Fresenius Medical Care AG
|
$22.41 | $27.17 | $13B | 11.66x | $0.81 | 3.64% | 0.59x |
|
IFRX
InflaRx NV
|
$0.91 | $8.84 | $66.6M | -- | $0.00 | 0% | 281.78x |
|
IMTX
Immatics NV
|
$10.35 | $18.75 | $1.4B | 42.21x | $0.00 | 0% | 24.29x |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FSNUY
Fresenius SE & Co. KGaA
|
38.45% | 2.011 | 42.39% | 0.68x |
|
BNTX
BioNTech SE
|
1.37% | 1.157 | 1.31% | 7.36x |
|
FMS
Fresenius Medical Care AG
|
44.79% | 1.034 | 84.8% | 0.80x |
|
IFRX
InflaRx NV
|
2.1% | -3.295 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.13% | 2.015 | 1.3% | 11.05x |
|
MDGEF
Medigene AG
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FSNUY
Fresenius SE & Co. KGaA
|
$1.8B | $616.9M | 4.9% | 8.16% | 8.61% | $704.8M |
|
BNTX
BioNTech SE
|
$668.2M | -$271M | -5.85% | -5.93% | -25.66% | $277M |
|
FMS
Fresenius Medical Care AG
|
$1.6B | $672.7M | 4.72% | 8.19% | 11.4% | $662.8M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$50.7M | -38.67% | -40.01% | -220.36% | -$68.9M |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- | -- |
Fresenius SE & Co. KGaA vs. Competitors
-
Which has Higher Returns FSNUY or BNTX?
BioNTech SE has a net margin of 6.94% compared to Fresenius SE & Co. KGaA's net margin of -33.61%. Fresenius SE & Co. KGaA's return on equity of 8.16% beat BioNTech SE's return on equity of -5.93%.
Company Gross Margin Earnings Per Share Invested Capital FSNUYFresenius SE & Co. KGaA24.76% $0.19 $37.2B BNTXBioNTech SE63.27% -$1.45 $22.9B -
What do Analysts Say About FSNUY or BNTX?
Fresenius SE & Co. KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand BioNTech SE has an analysts' consensus of $130.51 which suggests that it could grow by 43.13%. Given that BioNTech SE has higher upside potential than Fresenius SE & Co. KGaA, analysts believe BioNTech SE is more attractive than Fresenius SE & Co. KGaA.
Company Buy Ratings Hold Ratings Sell Ratings FSNUYFresenius SE & Co. KGaA0 0 0 BNTXBioNTech SE13 5 0 -
Is FSNUY or BNTX More Risky?
Fresenius SE & Co. KGaA has a beta of 0.810, which suggesting that the stock is 18.985% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.581, suggesting its more volatile than the S&P 500 by 58.073%.
-
Which is a Better Dividend Stock FSNUY or BNTX?
Fresenius SE & Co. KGaA has a quarterly dividend of $0.28 per share corresponding to a yield of 2.28%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius SE & Co. KGaA pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FSNUY or BNTX?
Fresenius SE & Co. KGaA quarterly revenues are $7.2B, which are larger than BioNTech SE quarterly revenues of $1.1B. Fresenius SE & Co. KGaA's net income of $497M is higher than BioNTech SE's net income of -$355M. Notably, Fresenius SE & Co. KGaA's price-to-earnings ratio is 19.47x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius SE & Co. KGaA is 1.08x versus 6.64x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FSNUYFresenius SE & Co. KGaA1.08x 19.47x $7.2B $497M BNTXBioNTech SE6.64x 191.55x $1.1B -$355M
-
Which has Higher Returns FSNUY or FMS?
Fresenius Medical Care AG has a net margin of 6.94% compared to Fresenius SE & Co. KGaA's net margin of 7.95%. Fresenius SE & Co. KGaA's return on equity of 8.16% beat Fresenius Medical Care AG's return on equity of 8.19%.
Company Gross Margin Earnings Per Share Invested Capital FSNUYFresenius SE & Co. KGaA24.76% $0.19 $37.2B FMSFresenius Medical Care AG27.4% $0.67 $29.5B -
What do Analysts Say About FSNUY or FMS?
Fresenius SE & Co. KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand Fresenius Medical Care AG has an analysts' consensus of $27.17 which suggests that it could grow by 21.22%. Given that Fresenius Medical Care AG has higher upside potential than Fresenius SE & Co. KGaA, analysts believe Fresenius Medical Care AG is more attractive than Fresenius SE & Co. KGaA.
Company Buy Ratings Hold Ratings Sell Ratings FSNUYFresenius SE & Co. KGaA0 0 0 FMSFresenius Medical Care AG2 3 1 -
Is FSNUY or FMS More Risky?
Fresenius SE & Co. KGaA has a beta of 0.810, which suggesting that the stock is 18.985% less volatile than S&P 500. In comparison Fresenius Medical Care AG has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.433%.
-
Which is a Better Dividend Stock FSNUY or FMS?
Fresenius SE & Co. KGaA has a quarterly dividend of $0.28 per share corresponding to a yield of 2.28%. Fresenius Medical Care AG offers a yield of 3.64% to investors and pays a quarterly dividend of $0.81 per share. Fresenius SE & Co. KGaA pays -- of its earnings as a dividend. Fresenius Medical Care AG pays out 57.49% of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FSNUY or FMS?
Fresenius SE & Co. KGaA quarterly revenues are $7.2B, which are larger than Fresenius Medical Care AG quarterly revenues of $5.9B. Fresenius SE & Co. KGaA's net income of $497M is higher than Fresenius Medical Care AG's net income of $469.1M. Notably, Fresenius SE & Co. KGaA's price-to-earnings ratio is 19.47x while Fresenius Medical Care AG's PE ratio is 11.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius SE & Co. KGaA is 1.08x versus 0.59x for Fresenius Medical Care AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FSNUYFresenius SE & Co. KGaA1.08x 19.47x $7.2B $497M FMSFresenius Medical Care AG0.59x 11.66x $5.9B $469.1M
-
Which has Higher Returns FSNUY or IFRX?
InflaRx NV has a net margin of 6.94% compared to Fresenius SE & Co. KGaA's net margin of -51538.49%. Fresenius SE & Co. KGaA's return on equity of 8.16% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital FSNUYFresenius SE & Co. KGaA24.76% $0.19 $37.2B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About FSNUY or IFRX?
Fresenius SE & Co. KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of $8.84 which suggests that it could grow by 868.56%. Given that InflaRx NV has higher upside potential than Fresenius SE & Co. KGaA, analysts believe InflaRx NV is more attractive than Fresenius SE & Co. KGaA.
Company Buy Ratings Hold Ratings Sell Ratings FSNUYFresenius SE & Co. KGaA0 0 0 IFRXInflaRx NV5 2 0 -
Is FSNUY or IFRX More Risky?
Fresenius SE & Co. KGaA has a beta of 0.810, which suggesting that the stock is 18.985% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.493, suggesting its more volatile than the S&P 500 by 49.333%.
-
Which is a Better Dividend Stock FSNUY or IFRX?
Fresenius SE & Co. KGaA has a quarterly dividend of $0.28 per share corresponding to a yield of 2.28%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius SE & Co. KGaA pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FSNUY or IFRX?
Fresenius SE & Co. KGaA quarterly revenues are $7.2B, which are larger than InflaRx NV quarterly revenues of $27.8K. Fresenius SE & Co. KGaA's net income of $497M is higher than InflaRx NV's net income of -$14.3M. Notably, Fresenius SE & Co. KGaA's price-to-earnings ratio is 19.47x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius SE & Co. KGaA is 1.08x versus 281.78x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FSNUYFresenius SE & Co. KGaA1.08x 19.47x $7.2B $497M IFRXInflaRx NV281.78x -- $27.8K -$14.3M
-
Which has Higher Returns FSNUY or IMTX?
Immatics NV has a net margin of 6.94% compared to Fresenius SE & Co. KGaA's net margin of -180.65%. Fresenius SE & Co. KGaA's return on equity of 8.16% beat Immatics NV's return on equity of -40.01%.
Company Gross Margin Earnings Per Share Invested Capital FSNUYFresenius SE & Co. KGaA24.76% $0.19 $37.2B IMTXImmatics NV-- -$0.33 $586.9M -
What do Analysts Say About FSNUY or IMTX?
Fresenius SE & Co. KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 81.16%. Given that Immatics NV has higher upside potential than Fresenius SE & Co. KGaA, analysts believe Immatics NV is more attractive than Fresenius SE & Co. KGaA.
Company Buy Ratings Hold Ratings Sell Ratings FSNUYFresenius SE & Co. KGaA0 0 0 IMTXImmatics NV9 0 0 -
Is FSNUY or IMTX More Risky?
Fresenius SE & Co. KGaA has a beta of 0.810, which suggesting that the stock is 18.985% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.675%.
-
Which is a Better Dividend Stock FSNUY or IMTX?
Fresenius SE & Co. KGaA has a quarterly dividend of $0.28 per share corresponding to a yield of 2.28%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius SE & Co. KGaA pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FSNUY or IMTX?
Fresenius SE & Co. KGaA quarterly revenues are $7.2B, which are larger than Immatics NV quarterly revenues of $23M. Fresenius SE & Co. KGaA's net income of $497M is higher than Immatics NV's net income of -$41.6M. Notably, Fresenius SE & Co. KGaA's price-to-earnings ratio is 19.47x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius SE & Co. KGaA is 1.08x versus 24.29x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FSNUYFresenius SE & Co. KGaA1.08x 19.47x $7.2B $497M IMTXImmatics NV24.29x 42.21x $23M -$41.6M
-
Which has Higher Returns FSNUY or MDGEF?
Medigene AG has a net margin of 6.94% compared to Fresenius SE & Co. KGaA's net margin of --. Fresenius SE & Co. KGaA's return on equity of 8.16% beat Medigene AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FSNUYFresenius SE & Co. KGaA24.76% $0.19 $37.2B MDGEFMedigene AG-- -- -- -
What do Analysts Say About FSNUY or MDGEF?
Fresenius SE & Co. KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand Medigene AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Fresenius SE & Co. KGaA has higher upside potential than Medigene AG, analysts believe Fresenius SE & Co. KGaA is more attractive than Medigene AG.
Company Buy Ratings Hold Ratings Sell Ratings FSNUYFresenius SE & Co. KGaA0 0 0 MDGEFMedigene AG0 0 0 -
Is FSNUY or MDGEF More Risky?
Fresenius SE & Co. KGaA has a beta of 0.810, which suggesting that the stock is 18.985% less volatile than S&P 500. In comparison Medigene AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock FSNUY or MDGEF?
Fresenius SE & Co. KGaA has a quarterly dividend of $0.28 per share corresponding to a yield of 2.28%. Medigene AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius SE & Co. KGaA pays -- of its earnings as a dividend. Medigene AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FSNUY or MDGEF?
Fresenius SE & Co. KGaA quarterly revenues are $7.2B, which are larger than Medigene AG quarterly revenues of --. Fresenius SE & Co. KGaA's net income of $497M is higher than Medigene AG's net income of --. Notably, Fresenius SE & Co. KGaA's price-to-earnings ratio is 19.47x while Medigene AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius SE & Co. KGaA is 1.08x versus -- for Medigene AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FSNUYFresenius SE & Co. KGaA1.08x 19.47x $7.2B $497M MDGEFMedigene AG-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 5
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 5
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
